Genfit Has Enroled its First Patient in a NASH Phase III Trial

11/03/2016 - 2 minutes

Genfit (France) has enroled their first patient in the highly anticipated phase III trial (RESOLVE-IT) for NASH, a fatty-liver disease currently without any approved treatment.

genfit_liver_nash_elafibranor_gft505This is good news for Genfit, which managed to kickstart a phase III trial for their lead candidate, Elafibranor, just one year after the read-out of the phase IIb results.

There is, of course, much expectation regarding the clinical development of this candidate. Non-alcoholic steatohepatitis (NASH) is a disease on the rise, linked to diabetes and obesity. It already affects about 30 million people worldwide – who have no treatment option so far.

This led to a drug race, involving Big Pharma names like AbbVie and Gilead, but also smaller players, such as DS Biopharma (Ireland) – which has an innovative bioactive lipid in phase I.

Given the hype, a lot of money is being moved around. Boehringer Ingelheim and Gilead both acquired candidates for NASH.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member